TABLE 1.
Demographic Data and Summary of Events
| All | Inducible LVWMA | No Inducible LVWMA | P-value | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Patients, % | n=221 | n=60 (27) | n=161 (73) | |
| Age, years | 63 ±12 | 62 ±12 | 63 ±12 | 0.56 |
| Weight, kg | 189 ±48 | 87±20 | 85 ±23 | 0.7 |
| BMI | 33 ±8 | 34 ±8 | 32 ±9 | 0.18 |
| LVEF, % | 59 ±11 | 51 ±12 | 62 ±10 | <0.0001 |
| Historical information (%) | ||||
| Prior Q-wave MI | 62 (28) | 22 (37) | 40 (25) | 0.08 |
| Prior Re-vascularization | 81 (37) | 32 (53) | 49 (30) | 0.001 |
| Prior PCI | 55 (25) | 24 (40) | 30 (19) | 0.001 |
| Prior CABG | 42 (19) | 16 (27) | 26 (16) | 0.08 |
| Hypertension | 162 (73) | 49 (82) | 113 (70) | 0.087 |
| Diabetes | 84 (38) | 30 (50) | 54 (34) | 0.025 |
| Hyperlipidemia | 127 (57) | 38 (63) | 89 (55) | 0.28 |
| Family History | 115 (52) | 31 (52) | 84 (52) | 0.95 |
| Smoking | 83 (38) | 26 (43) | 57 (35) | 0.28 |
| COPD/Asthma | 47 (21) | 9 (15) | 38 (24) | 0.17 |
| Congestive Heart Failure | 25 (11) | 11 (18) | 14 (9) | 0.044 |
| Medications (%) | ||||
| Digoxin | 13 (6) | 3 (5) | 10 (6) | 0.74 |
| Diuretic | 103 (47) | 33 (55) | 70 (43) | 0.13 |
| Beta Blocker | 77 (35) | 23 (38) | 54 (34) | 0.51 |
| Calcium Antagonist | 48 (22) | 18 (30) | 30 (19) | 0.069 |
| Aspirin | 110 (50) | 34 (57) | 76 (47) | 0.21 |
| Nitrate | 66 (30) | 27 (45) | 39 (24) | 0.0026 |
| ACE inhibitor/ARB | 62 (28) | 26 (43) | 36 (22) | 0.002 |
| Anti-coagulation | 18 (8) | 4 (7) | 14 (9) | 0.63 |
| Anti-Lipid | 86 (39) | 24 (40) | 62 (39) | 0.84 |
| Events (%) | ||||
| Cardiac Death | 21 (10) | 15 (25) | 6 (4) | <0.0001 |
| Myocardial infarction | 19 (11) | 10 (17) | 9 (6) | <0.01 |
| Revascularization | 46 (21) | 19 (32) | 27 (16) | 0.011 |
| Unstable angina | 46 (21) | 22 (37) | 24 (14) | <0.001 |
| Congestive Heart Failure | 17 (8) | 6 (10) | 11 (6) | 0.34 |
Values are expressed as n (%) unless otherwise indicated.
Abbreviations: ACE, angiotension converting enzyme; ARB, angiotension receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; LVWMA, left ventricular wall motion abnormalities; PCI, percutaneous coronary intervention.